TrialCompass™ TCL
Back to results
RecruitingPriority 4 · Lower priorityNCT06509945

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

ClinicalTrials.gov

Plain-language summary

This study is evaluating allogeneic peripheral blood stem cell transplantation as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 70 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

allogeneic peripheral blood stem cell transplantation (OTHER): Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.

Drugs / treatments
allogeneic peripheral blood stem cell transplantation
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

NCT06509945

Status: Recruiting | Priority: Lower

Plain-language summary

This study is evaluating allogeneic peripheral blood stem cell transplantation as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 70 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

allogeneic peripheral blood stem cell transplantation (OTHER): Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.

Drugs / treatments: allogeneic peripheral blood stem cell transplantation

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 50 patients

Primary endpoint: 1y and 2y-progression-free survival (PFS)

Ages: 18 Years to 70 Years

Start date: 2024-07-15 | Est. completion: 2026-07-15

Locations

0 US sites · 1 total

Contact

xianmin song, MD | shongxm@139.com | +862163240090

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (OTHER)

Tags

All T-cell lymphomas · Maintenance · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06509945

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.